Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2007-11-22 Investor Presentation
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Investor Presentation 2007
Investor Presentation Classification · 95% confidence The document is titled "Highlights from the Medivir R&D-Day currently underway" and is dated November 22, 2007. It details updates on pharmaceutical projects (Lipsovir® and MIV-701), including clinical trial progress (Phase III and Phase I results) and future regulatory timelines. This content is characteristic of an investor or research and development update presentation, often shared during an R&D Day or Investor Day. Since it is a summary of ongoing R&D progress and strategy updates aimed at investors, the most appropriate classification is Investor Presentation (IP). It is not a formal regulatory filing like a 10-K or IR, nor is it a general earnings release (ER) which focuses strictly on financial performance metrics. It is also not a Call Transcript (CT) as it is a written summary of presentations.
2007-11-22 English
Regulatory Filings 2007
Regulatory Filings Classification · 95% confidence The document is a press release dated 2007-11-21 announcing the initiation of a Phase IIa clinical trial for a drug candidate (TMC435350). It details the trial design, patient enrollment, and references prior Phase I results. This type of announcement, detailing clinical trial progress and scientific updates, is typically classified as an Investor Presentation (IP) if it were a formal deck, or often falls under general Regulatory Filings (RNS) or sometimes an Earnings Release (ER) if tied to quarterly results. However, given the specific focus on clinical trial progression and scientific data presentation (even if brief), and lacking the structure of a formal ER or the comprehensive nature of an IR, it best fits the general category for specific corporate updates that aren't standard financial reports. Since it is a press release announcing a specific corporate/scientific event, and it doesn't fit the other specific categories like DIV, DIRS, or 10-K, RNS (Regulatory Filings) is the most appropriate fallback for a non-standard, time-sensitive corporate announcement.
2007-11-21 English
Legal Proceedings Report 2007
Legal Proceedings Report Classification · 99% confidence The document is a press release dated 2007-11-21 announcing the start of a Phase IIa clinical study for a drug candidate (TMC435350). It details the study design (randomized, double-blind, placebo-controlled), dosage, patient population, and mentions results from previous Phase I studies. This content relates to ongoing research and development activities, specifically clinical trials. It is not a formal financial report (like 10-K or IR), an earnings release (ER), a management discussion (MDA), or a formal regulatory filing like a DIRS or MRQ. Since there is no specific category for 'Clinical Trial Announcement' or 'R&D Update', and the document is a general announcement about company activity, the most appropriate fallback category is 'Regulatory Filings' (RNS), as it is a formal public disclosure that doesn't fit the other specific financial or governance categories. Given the nature of the announcement (a press release about a clinical trial), RNS is the best fit among the provided options.
2007-11-21 Swedish
Regulatory Filings 2007
Regulatory Filings Classification · 95% confidence The document is a press release dated 2007-11-08 announcing the initiation of patient enrollment in a Phase IIb clinical trial for a drug (valomaciclovir) for shingles treatment. It contains quotes from executives and investigators discussing the drug's potential and the market need. This type of announcement, focusing on clinical trial progress and business updates outside of mandatory financial reporting (like 10-K, 10-Q, or specific earnings releases), is best classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were a slide deck. Since it is a standard press release detailing operational/clinical progress and does not fit the specific definitions for financial reports (10-K, IR, ER, MRQ), capital changes (CAP, SHA), or management changes (MANG), the most appropriate general category is Regulatory Filings (RNS), which serves as a broad category for non-standard regulatory announcements.
2007-11-08 English
Regulatory Filings 2007
Regulatory Filings Classification · 95% confidence The document is a press release dated 2007-11-08, written in Swedish, announcing that Epiphany Biosciences has initiated a Phase IIb clinical study for valacyclovir in shingles patients. It details the study's purpose, the drug's potential, and includes quotes from company executives (Epiphany and Medivir). This type of announcement, detailing operational progress (like starting a clinical trial) and strategic updates, is characteristic of a general corporate announcement or press release. Since it is not a formal regulatory filing like a 10-K, a specific financial report (IR, MRQ), or a transcript, it best fits the general 'Regulatory Filings' category (RNS) as a catch-all for significant, non-standardized corporate news, or potentially an 'LTR' if it were about legal proceedings, but here it is about clinical development. Given the options, RNS (Regulatory Filings/General Announcement) is the most appropriate fit for a press release detailing clinical trial initiation.
2007-11-08 Swedish
Major Shareholding Notification 2007
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding percentage for an issuer (Medivir Aktiebolag) by a holder (Handelsbanken Fonder AB). Specifically, it shows the 'Before the transaction' and 'After the transaction' share counts and voting rights percentages, noting the 'Reason for major shareholding notification Sell'. This structure perfectly matches the definition of a Major Shareholding Notification, which is categorized as 'MRQ' in the provided schema. The document is a direct notification of a change in significant ownership, not an announcement of a report or a general regulatory filing.
2007-11-01 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.